Internet of Events
Leaderboard
Traders
Markets
Hot Bets
Surveillance
Pricing
Log in
Get Access
Accrue
/
Home
/
Manifold Markets
/
Pain Relief vs Addiction: Will Vertex’s non-opioid (hopefully nonaddictive) Suzetrigine/VX-548 be FDA-approved in 2024?
Manifold
Resolved: NO
BINARY · cpmm-1
Pain Relief vs Addiction: Will Vertex’s non-opioid (hopefully nonaddictive) Suzetrigine/VX-548 be FDA-approved in 2024?
Yes
9%
Yes Pool
$343
No Pool
$31
Resolution
NO